When combined with the checkpoint inhibitor PD-1 blockade, the enhanced immunological response controlled the distal untreated tumors efficiently, by decreasing the expression of PD-L1 on tumor cells and reversing dysfunction of CTLs. The gene discussed is PDCD1; the disease is neoplasm.